LY293111

Gary K. Schwartz, MD

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of LY293111 in treating patients who have advanced solid tumors.

OBJECTIVES: I. Determine the maximum tolerated dose of LY293111 in patients with advanced solid tumors. II. Determine the safety profile and pharmacokinetics of this regimen in these patients. III. Determine the antitumor activity of this regimen in these patients.

OUTLINE: This is a dose escalation study. Patients receive oral LY293111 twice daily. Treatment continues for a maximum of 6 months in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of LY293111 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose limiting toxicity. Additional patients are treated at the MTD. Patients are followed at 30 days.

PROJECTED ACCRUAL: Approximately 24 patients will be accrued for this study.

LY293111 in Treating Patients With Advanced Solid Tumors

A Phase I Clinical and Pharmacokinetic Evaluation of LY293111 in Patients With Solid Tumors (Protocol H6H-MC-JEAI)

National Cancer Institute (NCI)

Memorial Sloan Kettering Cancer Center

Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Gemcitabine

Cisplatin

Antimetabolites

cisplatin

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine and cisplatin in patients with non-small cell lung cancer.

A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer

Randomized, Placebo-Controlled, Double-Blind, Phase 2 Study of Gemcitabine-Cisplatin Combined With Two Different Doses of LY293111 or Placebo in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

Eli Lilly and Company

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

placebo

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST)

The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.

A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer

A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
LY293111 in Treating Patients With Advanced Solid Tumors	NCT00006375	Unspecified Adu...	LY293111	18 Years -	Memorial Sloan Kettering Cancer Center
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer	NCT00069875	Carcinoma, Non-...	Gemcitabine LY293111 cisplatin	18 Years -	Eli Lilly and Company
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer	NCT00055250	Pancreatic Canc...	Gemcitabine LY293111 placebo	18 Years -	Eli Lilly and Company
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer	NCT00069875	Carcinoma, Non-...	Gemcitabine LY293111 cisplatin	18 Years -	Eli Lilly and Company
A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer	NCT00055250	Pancreatic Canc...	Gemcitabine LY293111 placebo	18 Years -	Eli Lilly and Company
A Study With Gemcitabine, Cisplatin, and LY293111 in Non-Small Cell Lung Cancer	NCT00069875	Carcinoma, Non-...	Gemcitabine LY293111 cisplatin	18 Years -	Eli Lilly and Company
LY293111 in Treating Patients With Advanced Solid Tumors	NCT00006375	Unspecified Adu...	LY293111	18 Years -	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for ly293111

Every month we try and update this database with for ly293111 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ly293111

Every month we try and update this database with for ly293111 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ly293111 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.